Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  CGC | T.WEED.DB

Canopy Growth Corporation is a cannabis and consumer packaged goods (CPG) company. The Company delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space. Its CPG portfolio includes gourmet wellness products by Martha Stewart CBD, and vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution, and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a diverse range of cannabis, hemp, and cannabis products in Canada. Its Rest-of-world cannabis segment includes the production, distribution, and sale of a diverse range of cannabis and hemp products internationally. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers.


TSX:WEED - Post by User

Bullboard Posts
Comment by Trennamon Jul 08, 2019 9:48am
83 Views
Post# 29895133

RE:Reviewing the Canopy Growth Ecosystem

RE:Reviewing the Canopy Growth Ecosystem
Brochstein is always a good read and insightful in his analysis. One of the handfull of people I regularly listen to. He's been around since the beginning and knows his sh%t as opposed to many others.



DSEEGS wrote:

Reviewing the Canopy Growth Ecosystem

Exclusive article by Alan Brochstein, CFA

Friends,

This weeks’s announcement by Canopy Growth that its Board of Directors had removed Co-Founder Bruce Linton from the company he started seven years ago surprised the industry. We are sad for our friend and colleague with how his time came to an abrupt end and congratulate him for all that he did for the company and the global industry.

Change at the top is nothing new for the sector, as several LPs have seen leadership changes through consolidation as well as internal changes. Aphria brought in outsider Irwin Simon, who is still Interim CEO but likely, in our view, to shed the “interim” shortly. Aurora Cannabis moved CEO and Co-Founder Terry Booth under the Executive Chairman. CannTrust named Peter Aceto to replace its founder late last year. Two years ago, Organigram brought in a new CEO, Greg Engel, who replaced its founder. Of course, Tilray had earlier replaced him as CEO. These companies are 6 of the current 7 leading LPs in terms of revenue, and there are examples from other companies as well.

While investors certainly want to know what lies ahead for Canopy Growth, there will likely be some uncertainty until a new CEO is named. In our view, the company should be able to attract some incredible talent, and we look forward to seeing this process play out. In the meantime, new CFO Mike Lee, a Constellation veteran, certainly has his eye on the ball. We highly recommend that readers review his strategic priorities that he shared on the conference call last month. Specifically, he called for reviewing the global ERP strategy, strengthening financial reporting and controls and accelerating acquisition integrations. All of this is designed to create scalable growth, and we expect that the new CEO picked by Constellation will be one the company expects can drive growth in a more scalable manner than the company has done thus far.

In the immediate aftermath, NY Representative Chuck Schumer was quick to affirm that Canopy Growth will be proceeding with its New York hemp activities, as reported by Marijuana Moment. Canopy Growth has an extensive ecosystem of strategic partners, and we think it would be wise for investors in those companies, many of which are publicly-traded, to affirm that those relationships will proceed under the new leadership. To be very clear, we have no reason to believe that they won’t, but we want to make sure our readers are aware of the several companies that may be facing some uncertainty during this leadership transition at Canopy Growth.

At the top of the list is Canopy Rivers, which also dismissed Linton from his roles there. The company was Bruce Linton’s idea, and it seeks to leverage Canopy Growth’s infrastructure and capital by providing financial and operating support to companies across the industry. Canopy Growth owns 27% of the issued shares and over 85% of the voting power.

Another obvious question is what the change means for Acreage Holdings. We checked in with CEO Kevin Murphy, who is highly optimistic that the affiliation will continue. As a reminder, he and his shareholders just received an option payment of $2.63 per share ($300 million in total) for a future potential acquisition when permissible at a the fixed share price of .5812 shares of Canopy for each share of Acreage. We interviewed Murphy earlier this year, and he shared his expectation that ultimately Constellation will buy in both Canopy Growth and his company.

Canopy Growth has two significant stakes in U.S. operators beyond its arrangement with Acreage Holdings, including non-voting stock in TerrAscend as well as warrants in SLANG Worldwide. One area where the company has forged several strategic partnerships is in extraction, with suppliers including MediPharm Labs, Neptune and Valens GroWorks, all publicly-traded, as well as HollyWeed North, which is expected to debut in public trading near the end of the year.

While many were surprised by the sudden move by the Canopy Growth Board of Directors, we think investors should be prepared for more changes ahead after a period of substantial M&A and capital raising and an evolving market that is becoming more global and supported by institutional investors.

 


Bullboard Posts